AI Engines For more Details: Perplexity Kagi Labs You
Sedation and Drowsiness: Zotepine can cause sedation and drowsiness, particularly when starting treatment or when the dosage is increased. This can impair alertness and concentration, affecting activities such as driving or operating machinery.
Weight Gain: Like many antipsychotic medications, zotepine is associated with weight gain, which may increase the risk of obesity and related health problems such as diabetes and cardiovascular disease.
Metabolic Effects: Zotepine can disrupt metabolic processes in the body, leading to increased levels of blood glucose, cholesterol, and triglycerides. This may contribute to the development of metabolic syndrome and an increased risk of cardiovascular complications.
Extrapyramidal Symptoms (EPS): Some patients may experience extrapyramidal symptoms such as tremors, muscle stiffness, restlessness, and involuntary movements (dyskinesia) while taking zotepine. These side effects are more common with typical antipsychotic medications but can also occur with atypical antipsychotics like zotepine.
Orthostatic Hypotension: Zotepine may cause a drop in blood pressure upon standing up from a sitting or lying position, leading to dizziness, lightheadedness, or fainting. This is known as orthostatic hypotension and can increase the risk of falls, particularly in elderly patients.
Anticholinergic Effects: Zotepine can block the activity of acetylcholine, a neurotransmitter involved in various bodily functions. This may result in dry mouth, constipation, urinary retention, blurred vision, and cognitive impairment.
Cardiac Effects: Rarely, zotepine may prolong the QT interval on an electrocardiogram (ECG), potentially leading to a type of irregular heart rhythm known as torsades de pointes. This risk is higher in patients with pre-existing cardiac conditions or those taking other medications that also prolong the QT interval.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 4.6 | 1.4 | 2.29 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 1.9 | 0.16 |
| Allergies | 7.3 | 4.7 | 0.55 |
| Allergy to milk products | 2 | 1 | 1 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.7 | 6.5 | 0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4 | 1.4 | 1.86 |
| Ankylosing spondylitis | 4.1 | 0.9 | 3.56 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 5.1 | 3 | 0.7 |
| Atherosclerosis | 1.8 | 3.3 | -0.83 |
| Atrial fibrillation | 4.1 | 2.5 | 0.64 |
| Autism | 10.2 | 10 | 0.02 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1.8 | 1.7 | 0.06 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.6 | 1.4 | -1.33 |
| Carcinoma | 3.8 | 2.6 | 0.46 |
| Celiac Disease | 3 | 4.3 | -0.43 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 4.5 | 7.7 | -0.71 |
| Chronic Kidney Disease | 2.8 | 2.8 | 0 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.7 | -0.7 |
| Chronic Urticaria (Hives) | 0.8 | 1.8 | -1.25 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 5 | 2.5 | 1 |
| Colorectal Cancer | 8.1 | 3.4 | 1.38 |
| Constipation | 1.8 | 2 | -0.11 |
| Coronary artery disease | 1.2 | 3 | -1.5 |
| COVID-19 | 9.5 | 11.8 | -0.24 |
| Crohn's Disease | 7.7 | 6.6 | 0.17 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.5 | -1.5 | |
| deep vein thrombosis | 2.4 | 1.4 | 0.71 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 10.6 | 10.5 | 0.01 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.8 | 2.3 | -1.87 |
| Endometriosis | 2.3 | 2 | 0.15 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.4 | 2.8 | -0.17 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 3.1 | 3.6 | -0.16 |
| Functional constipation / chronic idiopathic constipation | 5.5 | 3.7 | 0.49 |
| gallstone disease (gsd) | 2.5 | 1.3 | 0.92 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.2 | 0.25 |
| Generalized anxiety disorder | 1.8 | 3 | -0.67 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.7 | 1.9 | -0.12 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.5 | 1.6 | 1.19 |
| Heart Failure | 3.2 | 3.3 | -0.03 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.8 | 0.6 | 0.33 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 0.8 | 2.2 | -1.75 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.6 | 6.4 | -0.39 |
| Hypothyroidism | 0.8 | 1 | -0.25 |
| Hypoxia | 2.3 | 0.9 | 1.56 |
| IgA nephropathy (IgAN) | 1.6 | 4.3 | -1.69 |
| Inflammatory Bowel Disease | 7.3 | 10.3 | -0.41 |
| Insomnia | 2.3 | 3.5 | -0.52 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 6.5 | 6.2 | 0.05 |
| ischemic stroke | 3.1 | 1.1 | 1.82 |
| Liver Cirrhosis | 6.7 | 5.1 | 0.31 |
| Long COVID | 6.2 | 8.1 | -0.31 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | 1.6 | -4.33 |
| Lymphoma | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 1.2 | 2.4 | -1 |
| ME/CFS without IBS | 1.4 | 2.4 | -0.71 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.6 | 1 | 0.6 |
| Metabolic Syndrome | 6.9 | 8.9 | -0.29 |
| Mood Disorders | 10.2 | 8.4 | 0.21 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 6.4 | 7.3 | -0.14 |
| Multiple system atrophy (MSA) | 1.7 | 0.7 | 1.43 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.5 | -1.08 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.2 | 5.5 | -0.31 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.2 | 7.7 | 0.32 |
| obsessive-compulsive disorder | 5.1 | 3.6 | 0.42 |
| Osteoarthritis | 1.5 | 1.7 | -0.13 |
| Osteoporosis | 2.5 | 2.2 | 0.14 |
| pancreatic cancer | 0.9 | 0.6 | 0.5 |
| Parkinson's Disease | 8.3 | 7.5 | 0.11 |
| Polycystic ovary syndrome | 5.9 | 3.2 | 0.84 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 1.7 | 2.6 | -0.53 |
| Psoriasis | 3.8 | 4 | -0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.3 | 4.4 | 0.66 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 6.2 | 3.6 | 0.72 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 2.2 | 2.8 | -0.27 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
| Stress / posttraumatic stress disorder | 2.8 | 3.3 | -0.18 |
| Systemic Lupus Erythematosus | 3.4 | 2.3 | 0.48 |
| Tic Disorder | 1.5 | 2.3 | -0.53 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.5 | 4.6 | 0.2 |
| Type 2 Diabetes | 7.9 | 8.3 | -0.05 |
| Ulcerative colitis | 4.2 | 9.9 | -1.36 |
| Unhealthy Ageing | 4.8 | 2.9 | 0.66 |
| Vitiligo | 2.5 | 2 | 0.25 |
